Core Insights - The company achieved a revenue of RMB 482 million in the first half of 2025, representing a year-on-year growth of 31.7%, primarily driven by sales growth in the neurovascular and peripheral vascular intervention device segments [1] - Net profit increased by 76% to RMB 121.2 million, while adjusted net profit grew by 68.1% to RMB 131.4 million [1] - Research and development expenses rose by 19.7% to RMB 121.6 million, aimed at new product launches and innovation in the product pipeline [1] Revenue and Profitability - International business revenue saw a significant increase of 36.9%, with products now covering seven of the top ten global markets [1] - The company has established strategic partnerships with over 60 local partners, expanding its channel coverage to 52 countries and regions worldwide [1] Market Presence and Strategy - The company is actively conducting post-market clinical follow-up trials for CE-marked products in Europe to enhance quality recognition and brand awareness [1] - Support has been garnered from well-known hospital groups such as Asklepios and SANA, indicating strong market positioning and credibility [1]
归创通桥中期净利润同比增长76%